Anna Rossoshek is the head of quality and reporting in the NCATS Division of Preclinical Innovation (DPI), where she assures that DPI processes and procedures comply with NIH and NCATS policies and procedures for intramural science. She also serves as the program manager for the Toxicology in the 21st Century (Tox21) program.
Rossoshek joined NIH in June 2001 as a biologist at the National Human Genome Research Institute (NHGRI), working under the direction of Robert Nussbaum, M.D. In this capacity, she studied and developed genetic mouse models for familial forms of Parkinson’s disease and Lowe syndrome. Later, Rossoshek moved to NHGRI’s Division of Extramural Research to work on major scientific program initiatives, managing budgets and administering grants. In addition, she served as a liaison between extramural staff, administrative staff and the NHGRI Office of the Director. In April 2011, she joined the NIH Center for Translational Therapeutics, serving in a program and project management capacity and working with the team leaders of the Chemical Genomics Branch.
Rossoshek received her M.S. in biotechnology and M.B.A. from Johns Hopkins University.
Rossoshek’s research is focused on initiatives leading to cutting-edge technology on the translational science spectrum and small business innovation research.
Rossoshek’s professional interests include strategy and process development, policy formulation, programmatic planning and establishing new relationships and initiatives at NCATS.